Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Argus Health
Chinese Patent Office
UBS
Federal Trade Commission
Moodys

Generated: May 19, 2019

DrugPatentWatch Database Preview

ILEVRO Drug Profile

« Back to Dashboard

When do Ilevro patents expire, and when can generic versions of Ilevro launch?

Ilevro is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-eight patent family members in twenty-six countries.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nepafenac profile page.

Drug patent expirations by year for ILEVRO
Pharmacology for ILEVRO
Synonyms for ILEVRO
0J9L7J6V8C
2-(2-Amino-3-benzoyl-phenyl)-acetamide
2-(2-amino-3-benzoyl-phenyl)acetamide
2-(2-Amino-3-benzoylphenyl)acetamide
2-[2-amino-3-(benzoyl)phenyl]acetamide
2-[2-amino-3-(phenylcarbonyl)phenyl]acetamide
2-amino-3-benzoyl-benzeneacetamide
2-Amino-3-benzoyl-phenylacetamide
2-Amino-3-benzoylbenzeneacetamide
281N728
78281-72-8
A26218
AB0031799
AB01274763_02
AB01274763-01
AB1008448
AC-6949
AC1L45MC
AC1Q4ZKX
ACT02914
AHR 9434
AHR-9434
AK323236
AKOS005146108
AL 6515
AL-6515
Amfenac amide
AN-606
API0003541
AS-19176
BC677673
BCP21333
BDBM50228731
Benzeneacetamide, 2-amino-3-benzoyl-
BRD-K04112579-001-02-1
CAS-78281-72-8
CHEBI:75922
CHEMBL1021
CN0055
CS-0899
D05143
DB06802
DSSTox_CID_28564
DSSTox_GSID_48638
DSSTox_RID_82836
DTXSID0048638
EX-A1350
FT-0080494
FT-0603701
GTPL7564
HMS3654P07
HY-17357
I14-1056
J-507774
KB-58126
KS-000011BS
LS-186492
LS-187354
MFCD08067732
MLS003915618
MLS004774140
MLS006010644
MolPort-003-987-236
N0932
NCGC00185741-01
NCGC00185741-02
Nepafena
Nepafenac
Nepafenac (JAN/USAN/INN)
Nepafenac [USAN:INN:BAN:JAN]
Nepafenac [USAN]
Nepafenac, >=98% (HPLC)
nepafenaco
nepafenacum
Nevanac
Nevanac (TN)
PubChem17348
QEFAQIPZVLVERP-UHFFFAOYSA-N
RL05033
s1255
SC-20092
SCHEMBL93835
SMR002529588
SR-01000931908
SR-01000931908-2
STL451069
SW219197-1
TL8005351
Tox21_112985
Tox21_112985_1
UNII-0J9L7J6V8C
W-5364
X5012
ZINC5162311

US Patents and Regulatory Information for ILEVRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for ILEVRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ILEVRO
Drugname Dosage Strength RLD Date
➤ Subscribe Ophthalmic Suspension 0.3% ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for ILEVRO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0999825 CA 2013 00055 Denmark ➤ Try a Free Trial PRODUCT NAME: NEPAFENAC (3 MG/ML), HERUNDER NEPAFENAC I KOMBINATION MED GLACTOMANNANPOLYMERER, ISAER 3 MG/ML NEPAFENAC I KOMBINATION MED GALACTOMANNANPOLYMERER, SAMT OFTALMISKE SAMMENSAETNINGER DERAF; REG. NO/DATE: EU1/07/433/002 20130503
0999825 122013000085 Germany ➤ Try a Free Trial PRODUCT NAME: NEPAFENAC (OPHTHALMISCHE SUSPENSION); REGISTRATION NO/DATE: EU 1/07/433/002 20130503
0999825 92301 Luxembourg ➤ Try a Free Trial PRODUCT NAME: NEPAFENAC-SUSPENSION OPHTALMIQUE
0716600 C00716600/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: NEPAFENAC; REGISTRATION NUMBER/DATE: SWISSMEDIC 58745 24.09.2008
0999825 C300622 Netherlands ➤ Try a Free Trial PRODUCT NAME: NEPAFENAC; REGISTRATION NO/DATE: EU/1/07/433/002 20130503
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Medtronic
McKesson
Accenture
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.